Open Access

Exosomal long non‑coding RNA DLX6‑AS1 as a potential diagnostic biomarker for non‑small cell lung cancer

  • Authors:
    • Xilin Zhang
    • Huihui Guo
    • Ying Bao
    • Huanming Yu
    • Dong Xie
    • Xiang Wang
  • View Affiliations

  • Published online on: September 19, 2019     https://doi.org/10.3892/ol.2019.10892
  • Pages: 5197-5204
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Distal‑less homeobox 6 antisense RNA 1 (DLX6‑AS1) is upregulated in various solid tumors and serves a critical role in the tumorigenesis of cancer. However, to the best of our knowledge, the expression of circulating DLX6‑AS1 and its role in the diagnosis of non‑small cell lung cancer (NSCLC) have not been previously clarified. The aim of the present study was to investigate the expression and clinical significance of circulating DLX6‑AS1 using reverse transcription‑quantitative PCR in serum and exosomes derived from patients with NSCLC and healthy donors. The diagnostic value of circulating DLX6‑AS1 was identified by receiver operating characteristic curve (ROC) analysis. First, it was revealed that the expression levels of DLX6‑AS1 were significantly increased in tumor tissues compared with in adjacent normal tissues. In addition, DLX6‑AS1 was highly expressed in NSCLC cell lines compared with in BEAS‑2B cells. DLX6‑AS1‑knockdown inhibited cell proliferation and migration in vitro. It was subsequently demonstrated that the serum DLX6‑AS1 level was significantly higher in patients with NSCLC compared with in healthy controls. Additionally, the higher DLX6‑AS1 expression was associated with advanced disease stage, positive lymph node metastasis and poor tumor differentiation of NSCLC. ROC analysis demonstrated that the sensitivity and specificity of DLX6‑AS1 were higher than those of CYFRA21‑1, which is a serum marker for NSCLC. Finally, exosomal DLX6‑AS1 expression was increased in patients with NSCLC compared with in healthy controls. The present data implied that circulating DLX6‑AS1 was mainly incorporated into exosomes, providing a novel potential diagnostic marker for NSCLC.
View Figures
View References

Related Articles

Journal Cover

November-2019
Volume 18 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang X, Guo H, Bao Y, Yu H, Xie D and Wang X: Exosomal long non‑coding RNA DLX6‑AS1 as a potential diagnostic biomarker for non‑small cell lung cancer. Oncol Lett 18: 5197-5204, 2019
APA
Zhang, X., Guo, H., Bao, Y., Yu, H., Xie, D., & Wang, X. (2019). Exosomal long non‑coding RNA DLX6‑AS1 as a potential diagnostic biomarker for non‑small cell lung cancer. Oncology Letters, 18, 5197-5204. https://doi.org/10.3892/ol.2019.10892
MLA
Zhang, X., Guo, H., Bao, Y., Yu, H., Xie, D., Wang, X."Exosomal long non‑coding RNA DLX6‑AS1 as a potential diagnostic biomarker for non‑small cell lung cancer". Oncology Letters 18.5 (2019): 5197-5204.
Chicago
Zhang, X., Guo, H., Bao, Y., Yu, H., Xie, D., Wang, X."Exosomal long non‑coding RNA DLX6‑AS1 as a potential diagnostic biomarker for non‑small cell lung cancer". Oncology Letters 18, no. 5 (2019): 5197-5204. https://doi.org/10.3892/ol.2019.10892